These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 33266235)

  • 21. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
    Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
    Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colon cancer checks in when bile acids check out: the bile acid-nuclear receptor axis in colon cancer.
    Tang Q; Evans RM
    Essays Biochem; 2021 Dec; 65(6):1015-1024. PubMed ID: 34414429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions between bile salts, gut microbiota, and hepatic innate immunity.
    Schubert K; Olde Damink SWM; von Bergen M; Schaap FG
    Immunol Rev; 2017 Sep; 279(1):23-35. PubMed ID: 28856736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment.
    Zhu L; Baker RD; Zhu R; Baker SS
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):3-5. PubMed ID: 29697548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.
    Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q
    Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Bile Acids in Metabolic Control.
    Molinaro A; Wahlström A; Marschall HU
    Trends Endocrinol Metab; 2018 Jan; 29(1):31-41. PubMed ID: 29195686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.
    Pereira-Fantini PM; Lapthorne S; Joyce SA; Dellios NL; Wilson G; Fouhy F; Thomas SL; Scurr M; Hill C; Gahan CG; Cotter PD; Fuller PJ; Hardikar W; Bines JE
    J Hepatol; 2014 Nov; 61(5):1115-25. PubMed ID: 24999016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bile Acids Activated Receptors Regulate Innate Immunity.
    Fiorucci S; Biagioli M; Zampella A; Distrutti E
    Front Immunol; 2018; 9():1853. PubMed ID: 30150987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.
    Baghdasaryan A; Claudel T; Gumhold J; Silbert D; Adorini L; Roda A; Vecchiotti S; Gonzalez FJ; Schoonjans K; Strazzabosco M; Fickert P; Trauner M
    Hepatology; 2011 Oct; 54(4):1303-12. PubMed ID: 22006858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-talk between bile acids and intestinal microbiota in host metabolism and health.
    Nie YF; Hu J; Yan XH
    J Zhejiang Univ Sci B; 2015 Jun; 16(6):436-46. PubMed ID: 26055905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bile Acid Metabolism in Liver Pathobiology.
    Chiang JYL; Ferrell JM
    Gene Expr; 2018 May; 18(2):71-87. PubMed ID: 29325602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Reich M; Klindt C; Deutschmann K; Spomer L; Häussinger D; Keitel V
    Dig Dis; 2017; 35(3):235-240. PubMed ID: 28249265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice.
    Zheng X; Huang F; Zhao A; Lei S; Zhang Y; Xie G; Chen T; Qu C; Rajani C; Dong B; Li D; Jia W
    BMC Biol; 2017 Dec; 15(1):120. PubMed ID: 29241453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity.
    Münzker J; Haase N; Till A; Sucher R; Haange SB; Nemetschke L; Gnad T; Jäger E; Chen J; Riede SJ; Chakaroun R; Massier L; Kovacs P; Ost M; Rolle-Kampczyk U; Jehmlich N; Weiner J; Heiker JT; Klöting N; Seeger G; Morawski M; Keitel V; Pfeifer A; von Bergen M; Heeren J; Krügel U; Fenske WK
    Microbiome; 2022 Jun; 10(1):96. PubMed ID: 35739571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of bile acids in the therapy of selected diseases].
    Boguszewska A; Kiersztan A
    Postepy Biochem; 2024 Jan; 69(4):298-309. PubMed ID: 39012695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine and paracrine role of bile acids.
    Keitel V; Kubitz R; Häussinger D
    World J Gastroenterol; 2008 Oct; 14(37):5620-9. PubMed ID: 18837077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bile Acids and Portal Hypertension.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
    Chiang JYL; Ferrell JM
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation.
    Pols TW; Noriega LG; Nomura M; Auwerx J; Schoonjans K
    J Hepatol; 2011 Jun; 54(6):1263-72. PubMed ID: 21145931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
    Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
    Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.